# Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

> **NCT05675436** · — · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 6 (actual)

## Conditions studied

- Sickle Cell Anemia
- Sickle Cell Thalassemia
- Sickle Cell Pain
- Hbss
- Hbsc
- Sickle Beta Thalassemia
- Sickle Beta Zero Thalassemia
- Sickle Cell Syndrome Variant

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05675436
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-09
- **Primary completion:** 2027-10-27
- **Final completion:** 2027-10-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675436, "Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05675436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*